Aptevo reported new interim data from two trials of mipletamig combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are elderly or unfit for intensive chemotherapy. In 28 evaluable frontline patients, the combination showed an 86% clinical benefit rate and 0% cytokine release syndrome. Aptevo said 79% achieved complete remission or complete remission with incomplete blood marker recovery, and 61% achieved complete remission. Among patients who achieved complete remission or complete remission with incomplete blood marker recovery, 55% reached measurable residual disease-negative blast reductions, and 35% of remissions occurred in patients with TP53 mutations. The company did not state that these results were previously presented or will be presented in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-100539), on March 11, 2026, and is solely responsible for the information contained therein.
Comments